Artal Group’s Design Therapeutics DSGN Stock Holding History

Artal Group’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-400,000	Closed	-$5.6M	–	143
2022 Q2	$5.6M	Hold	400,000	–	–	0.3%	55
2022 Q1	$6.46M	Hold	400,000	–	–	0.27%	70
2021 Q4	$8.56M	Hold	400,000	–	–	0.23%	74
2021 Q3	$5.88M	Hold	400,000	–	–	0.13%	110
2021 Q2	$7.96M	Hold	400,000	–	–	0.16%	99
2021 Q1	$12M	Buy	+400,000	New	+$13.5M	0.21%	92

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group's DSGN Position: Q3 2022 in Review

Artal Group sold out of Design Therapeutics (DSGN) in Q3 2022, closing a stake of 400,000 shares — an estimated $5.6M sold.

Artal Group first reported a position in DSGN in Q1 2021 and held it in 6 quarters. The position peaked at $12M in Q1 2021. 79 funds tracked by Wall St. Rank hold DSGN as of Q3 2022.

Artal Group reported no remaining Design Therapeutics position as of Q3 2022 after selling out during the quarter.
Artal Group sold 400,000 Design Therapeutics shares in Q3 2022, an estimated $5.6M.
Artal Group first reported a position in Design Therapeutics in Q1 2021 and held it in 6 quarters.
Artal Group's Design Therapeutics position peaked at $12M in Q1 2021.
79 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2022.

Based on Artal Group's 13F filing for Q3 2022, filed 14 Nov 2022.